Molecular Genetics of Arrhythmias and Cardiovascular Conditions Associated with Arrhythmias

PACE - Pacing and Clinical Electrophysiology

Volumn 26, Issue 11, 2003, Pages 2194-2208

  Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; ALPHA CRYSTALLIN; ANTIPORTER; BETA CRYSTALLIN; CELL PROTEIN; CONNECTIN; CYTOSKELETON PROTEIN; DESMIN; DESMOPLAKIN; DYSTROPHIN; EMERIN; ION CHANNEL; LAMIN A; LAMIN C; LIM PROTEIN; MUSCLE PROTEIN; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; PLAKOGLOBIN; RYANODINE RECEPTOR; SARCOGLYCAN; TROPOMYOSIN; TROPONIN C; TROPONIN I; TROPONIN T;

ATRIOVENTRICULAR BLOCK; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BRUGADA SYNDROME; CARDIOMYOPATHY; GENE IDENTIFICATION; GENE LOCUS; GENETIC DISORDER; GENOTYPE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DILATATION; HEART VENTRICLE TACHYCARDIA; HEREDITY; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; MOLECULAR GENETICS; PHENOTYPE; REVIEW; SINUS ARREST; SINUS NODE DYSFUNCTION; TORSADE DES POINTES; WOLFF PARKINSON WHITE SYNDROME;

ARRHYTHMIA; CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR BIOLOGY;

EID: 0242468468     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2003.00345.x     Document Type: Review

References (134)

1. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291:1304-1351.
2. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol 1992; 20:1391-1396.
3. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101:510-515.
4. Shimizu W, Antzelevitch C, Suyama K, et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2000; 11:1320-1329.
5. Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. Circulation 2000; 102:2509-2515.
6. Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome: Consensus report. Circulation 2002; 106:2514-2519.
7. Vatta M, Dumaine R, Varghese G, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002;11:337-345.
8. Brugada P, Brugada J, Brugada R. Arrhythmia induction by antiarrhythmic drugs. PACE 2000; 23:291-292.
9. Miyazaki T, Mitamura H, Miyoshi S, et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996; 27:1061-1070.
10. Babaliaros VC, Hurst JW. Tricyclic antidepressants and the Brugada syndrome: An example of Brugada waves appearing after the administration of desipramine. Clin Cardiol 2002; 25:395-398.
11. Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 2002; 346:1591-1592.
12. Tada H, Sticherling C, Oral H, et al. Brugada syndrome mimicked by tricyclic antidepressant overdose. J Cardiovasc Electrophysiol 2001; 12:275.
13. Pastor A, Nunez A, Cantale C, et al. Asymptomatic Brugada syndrome case unmasked during dimenhydrinate infusion. J Cardiovasc Electrophysiol 2001; 12:1192-1194.
14. Ortega-Carnicer J, Bertos-Polo J, Gutierrez-Tirado C. Aborted sudden death, transient Brugada pattern, and wide QRS dysrrhythmias after massive cocaine ingestion. J Electrocardiol 2001; 34:345-349.
15. Nogami A, Nakao M, Kubota S, et al. Enhancement of J-ST-segment elevation by the glucose and insulin test in Brugada syndrome. PACE 2003; 26:332-337.
16. Antzelevitch C. The Brugada syndrome: Ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001; 12:268-272.
17. Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation 1996; 93:372-379.
18. Antzelevitch C. The Brugada syndrome: Ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001; 12:268-272.
19. Gussak I, Antzelevitch C, Bjerregaard P, et al. The Brugada syndrome: Clinical, electrophysiological and genetic aspects. J Am Coll Cardiol 1999; 33:5-15.
20. Yan GX, Antzelevitch C. Cellular basis for the Brugada Syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 1999; 100:1660-1666.
21. Lukas A, Antzelevitch C. Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia. The antiarrhythmic effects of 4-aminopyridine. Cardiovasc Res 1996; 32:593-603.
22. Antzelevitch C, Brugada P, Brugada J, et al. Brugada Syndrome: A Decade of Progress. Circ Res 2002; 91:1114-1118.
23. Kurita T, Shimizu W, Inagaki M, et al. The electrophysiologic mechanism of ST-segment elevation in Brugada syndrome. J Am Coll Cardiol 2002; 40:330-334.
24. Di Diego JM, Cordeiro JM, Goodrow RJ, et al: Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002; 106:2004-2011.
25. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 1998; 392:293-296.
26. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; 105:1342-1347.
27. Tan HL, Bezzina CR, Smits JP, et al. Genetic control of sodium channel function. Cardiovasc Res 2003; 57:961-973.
28. Baiser JR. The cardiac sodium channel: Gating function and molecular pharmacology. J Mol Cell Cardiol 2001; 33:599-613.
29. Dumaine R, Towbin JA, Brugada P, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res 1999; 85:803-809.
30. Antzelevitch C, Brugada R. Fever and the Brugada Syndrome. PACE 2002; 25:1637-1639.
31. Weiss R, Barmada MM, Nguyen T, et al. Clinical and molecular heterogeneity in the Brugada syndrome. A novel gene locus on chromosome 3 Circulation 2002; 105:707-713.
32. Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: Electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 2002; 40:350-356.
33. Schwartz PJ. The idiopathic long QT syndrome: Progress and questions. Am Heart J 1985; 109:399-411.
34. Moss AJ, Schwartz PJ, Crampton RS, et al. The Long QT Syndrome: Prospective longitudinal study of 328 families. Circulation 1991;84:1136-1144.
35. Zipes DP. The long QT interval syndrome: A Rosetta stone for sympathetic related ventricular tachyarrhythmias. Circulation 1991; 84:1414-1419.
36. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80:805-811.
37. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421:634-639.
38. Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001; 105:511-519.
39. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80:795-803.
40. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12:17-23.
41. Ks function. Nat Genet 1997; 17:338-340.
42. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis 2001; 43:1-45.
43. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999; 42:270-283.
44. Sipido KR, Volders PG, De Groot SH, et al. Enhanced Ca(2+) release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: Potential link between contractile adaptation and arrhythmogenesis. Circulation 2000; 102:2137-2144.
45. Volders PG, Sipido KR, Vos MA, et al. Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation 1999; 100:2455-2461.
46. Undrovinas AI, Maltsev VA, Sabbah HN. Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell Mol Life Sci 1999; 55:494-505.
47. Maltsev VA, Sabbah HN, Higgins RS, et al. Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation 1998; 98:2545-2552.
48. Antzelevitch C, Dumaine R. Electrical Heterogeneity in the Heart: Physiological, Pharmacological and Clinical Implications. In Page E, Fozzard HA, Solaro RJ (eds): Handbook of Physiology. The Heart. New York, Oxford University Press, 2002, pp. 654-692.
49. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the Long QT syndrome. Curr Opin Cardiol 2002; 17:43-51.
50. Shimizu W, Antzelevitch C. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 2000; 102:706-712.
51. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103:89-95.
52. Shimizu W, Antzelevitch C. Cellular basis for the electrocardiographic features of the LQT1 form of the long QT syndrome: Effects of b-adrenergic agonists, antagonists and sodium channel blockers on transmural dispersion of repolarization and Torsade de Pointes. Circulation 1998; 98:2314-2322.
53. Ali RH, Zareba W, Moss A, et al. Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. Am J Cardiol 2000; 85:457-461.
54. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing Torsade de Pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997; 96:2038-2047.
55. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000; 35:778-786.
56. Noda T, Takaki H, Kurita T, et al. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and forms of congenital long QT syndrome. Eur Heart J 2002; 23:975-983.
57. Antzelevitch C. Sympathetic modulation of the long QT syndrome. Eur Heart J 2002; 23:1246.
58. Keating MT, Atkinson DL, Dunn C, et al. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science 1991; 252:704-706.
59. Keating MT, Atkinson DL, Dunn C, et al. Consistent linkage of the long QT syndrome to the Harvey ras-1 locus on chromosome 11. Am J Hum Genet 1991; 49:1335-1339.
60. Benhorin J, Kalman YM, Medina A, et al. Evidence of genetic heterogeneity in the long QT syndrome. Science 1993; 260:1960-1962.
61. Curran ME, Atkinson DL, Timothy KW, et al. Locus heterogeneity of autosomal dominant long QT syndrome. J Clin Invest 1993; 92:799-803.
62. Bruggemann A, Pardo LA, Stuhmer W, et al. Ether-a-go-go encodes a voltage-gated channel permeable to K+ and Ca2+ and modulated by cAMP. Nature 1993; 365:445-448.
63. Warmke J, Drysdale R, Ganetzky B. A distinct potassium channel polypeptide encoded by the Drosophila eag locus. Science 1991; 252:1560-1562.
64. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in drosophila and mammals. Proc Natl Acad Sci USA 1994; 91:3438-3442.
65. Jiang C, Atkinson DL, Towbin JA, et al. Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. Nat Genet 1994; 8:141-147.
66. Trudeau MC, Warmke JW, Ganetzky B, et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995; 269:92-95.
67. Kr potassium channel. Cell 1995; 81:299-307.
68. Schott JJ, Charpentier F, Peltier S, et al. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995; 57:1114-1122.
69. Takumi T, Ohkubo H, Nakanishi S. Cloning of a membrane protein that induces a slow voltage-gated potassium current. Science 1988; 242:1042-1045.
70. Duggal P, Vesely MR, Wattanasirichaigoon D, et al. Mutation of the gene for IsK associated with both Jervell and Lange- Nielsen and Romano-Ward forms of Long-QT syndrome. Circulation 1998; 97:142-146.
71. Zhang M, Jiang M, Tseng GN. minK-related peptide 1 associates with Kv4.2 and modulates its gating function: potential role as beta subunit of cardiac transient outward channel? Circ Res 2001; 88:1012-1019.
72. Neyroud N, Tesson F, Denjoy I, et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet 1997; 15:186-189.
73. Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92:2929-2934.
74. Ali RH, Zareba W, Moss AJ, et al. Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. Am J Cardiol 2000; 85:457-461.
75. Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000; 102:2849-2855.
76. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 1998; 339:960-965.
77. Windle JR, Geletka RC, Moss AJ, et al. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A: DeltaKPQ mutation. Ann Noninvasive Electrocardiol 2001; 6:153-158.
78. Roden DM. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 2001; 50:224-231.
79. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing Torsade de Pointes in LQT2 as well as LQT3 models of the long QT syndrome.(abstract) PACE 1997; 20:1234.
80. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002; 297:1333-1336.
81. Camm AJ, Janse MJ, Roden DM, et al. Congenital and acquired long QT syndrome. Eur. Heart J 2000; 21:1232-1237.
82. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104:3081-3086.
83. Probst V, Kyndt F, Potet F, et al. Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenegre disease. J Am Coll Cardiol 2003; 41:643-652.
84. Laitinen PJ, Brown KM, Piippo K, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001; 103:485-490.
85. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106:69-74.
86. Marks AR, Priori S, Memmi M, et al. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. J Cell Physiol 2002; 190:1-6.
87. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69:1378-1384.
88. Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. (comments) N Engl J Med 1997; 336:905-911.
89. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation Science 2003; 299:251-254.
90. Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001; 344:1823-1831.
91. Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001; 10:1215-1220.
92. Gollob MH, Seger JJ, Gollob TN, et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001; 104:3030-3033.
93. Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2002; 2:145-166.
94. Nikoskelainen EK, Savontaus ML, Huoponen K, et al. Preexcitation syndrome in Leber's hereditary optic neuropathy. Lancet 1994; 344:857-858.
95. Corrado D, Fontaine G, Marcus FI, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation 2000; 101:E101-E106.
96. Corrado D, Basso C, Buja G, et al. Right bundle branch block, right precordial ST-segment elevation, and sudden death in young people. Circulation 2001; 103:710-717.
97. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: A multicenter study. J Am Coll Cardiol 1997; 30:1512-1520.
98. McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000; 355:2119-2124.
99. Tiso N, Stephan DA, Nava A, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10:189-194.
100. Rampazzo A, Nava A, Malacrida S, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2002; 71:1200-1206.
101. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103:196-200.
102. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 2000; 101:365-376.
103. Towbin JA, Bowles NE. The failing heart. Nature 2002: 415:227-233.
104. Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996; 276:199-204.
105. McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47:532-538.
106. Maron B J, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiornyopathy-related death: Revisited in a large non-referral-based patient population. Circulation 2000; 102:858-864.
107. Varnava AM, Elliott PM, Baboonian C, et al. Hypertrophic cardiomyopathy: Histopathological features of sudden death in cardiac troponin T disease. Circulation 2001; 104:1380-1384.
108. Maron BJ, Anan TJ, Roberts WC. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation 1981; 63:882-894.
109. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92:785-789.
110. Berger RD, Kasper EK, Baughman KL, et al. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 1997; 96:1557-1565.
111. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001; 33:655-670.
112. Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet 1997; 17:190-193.
113. Ashizawa T, Subramony SH. What is Kearns-Sayre syndrome after all? Arch Neurol 2001; 58:1053-1054.
114. Korade-Mirnics Z, Babitzke P, Huffman E. Myotonic dystrophy: molecular windows on a complex etiology. Nucleic Acids Res 1998; 26:1363-1368.
115. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29:465-468.
116. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation. Cell 1990; 62:999-1006.
117. Mestroni L, Rocco C, Gregori D, et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol 1999; 34:181-190.
118. Kasper EK, Agema WR, Hutchins GM, et al. The causes of dilated cardiomyopathy: A clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994; 23:586-590.
119. D'Adamo P, Fassone L, Gedeon A, et al. The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet 1997; 61:862-867.
120. Kamisago M, Sharma SD, DePalma SR, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000; 343:1688-1696.
121. Brugada R, Roberts R. The molecular genetics of arrhythmias and sudden death. Clin Cardiol 1998; 21:553-560.
122. Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341:1715-1724.
123. Dalakas MC, Park KY, Semino-Mora C, et al. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000; 342:770-780.
124. Muntoni F, Wilson L, Marrosu G, et al. A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. J Clin Invest 1995; 96:693-699.
125. Armoundas AA, Tomaselli GF. Electrical and Structural Remodeling of the Ventricular Myocardium in Disease. In HM Gussak, C Antzelevitch (eds.): Cardiac Repolarization. Bridging Basic and Clinical Science. Totowa NJ, Humana Press, 2003, pp. 127-152.
126. Bryant SM, Shipsey SJ, Hart G. Regional differences in electrical and mechanical properties of myocytes from guinea-pig hearts with mild left ventricular hypertrophy. Cardiovasc Res 1997; 35:315-323.
127. Keung ECH, Aronson RS. Transmembrane action potentials and the electrocardiogram in rats with renal hypertension. Cardiovasc Res 1981; 15:611-614.
128. McIntosh MA, Cobbe SM, Smith GL. Heterogeneous changes in action potential and intracellular Ca2+ in left ventricular myocyte sub-types from rabbits with heart failure. Cardiovasc Res 2000; 45:397-409.
129. Barr CS, Naas A, Freeman M, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994; 343:327-329.
130. Kaab S, Nuss HB, Chiamvimonvat N, et al. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 1996; 78:262-273.
131. Vos MA, van Opstal JM, Leunissen JD, et al. Electrophysiologic parameters and predisposing factors in the generation of druginduced Torsade de Pointes arrhythmias. Pharmacol Ther 2001; 92:109-122.
132. Marban E. Heart failure: The electrophysiologic connection. J Cardiovasc Electrophysiol 1999; 10:1425-1428.
133. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999; 42:270-283.
134. Ramakers C, Vos MA, Doevendans PA, et al. Coordinated downregulation of KCNQ1 and KCNE1 expression contributes to reduction of I(Ks) in canine hypertrophied hearts. Cardiovasc Res 2003; 57:486-496.